Diabetic Footwear Market

Two figures sit far apart in this trade: 589 million adults live with diabetes, yet Medicare paid just over USD 143 million for therapeutic shoes and inserts across calendar years 2024 and 2025 combined, a total the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS) put under audit on 29 May 2026. Diabetic footwear covers extra-depth diabetic shoes, multi-density diabetic inserts, custom-molded diabetic shoes, wound care and healing shoes, and diabetic sandals and slippers built to protect a neuropathic, deformed or recently ulcerated foot. Douglas Insights counts 41.27 million pairs dispensed in 2025 at an average manufacturer price of USD 72.86, and that product comes to USD 3.01 billion. The Diabetic Footwear Market reaches USD 5.42 billion by 2035, a revenue compound annual growth rate (CAGR) of 6.06% built from 4.6% pair growth and 1.4% price growth. The model sits in our diabetes devices coverage and follows the published Douglas Insights research methodology.

Which diabetic footwear product makes the money: extra-depth shoes, inserts or custom-molded pairs?

Extra-depth diabetic shoes make the most money, USD 1.26 billion or 41.8% of 2025 diabetic footwear revenue. The depth-inlay pair is the default prescription for an at-risk foot and the only shoe most payers fund every calendar year. Inserts follow at 23.7%, and sandals grow fastest.

Extra-depth diabetic shoes hold USD 1.26 billion since their added internal volume is what lets a clinician fit a pressure-relieving insert at all; they grow 5.45% a year to USD 2.14 billion. Multi-density diabetic inserts take USD 712.6 million, a 23.7% slice, because coverage rules allow three insert pairs for each depth pair, which turns the insert into the repeat sale of the category. Custom-molded diabetic shoes earn USD 378.9 million, or 12.6%: each pair is built over a cast or scan of a Charcot or partially amputated foot, so the price is high and the count is small, and growth is the slowest at 4.85%.

Wound care and healing shoes account for USD 369.8 million, a 12.3% share, sold to patients with an open ulcer or straight after forefoot surgery. Diabetic sandals and slippers are the smallest product at USD 288.7 million, or 9.6%. They are also the fastest grower at 7.75% a year, reaching USD 609.0 million in 2035, because warm-climate buyers in Asia Pacific and Latin America wear open footwear indoors and outdoors for most of the year.

Why are neuropathic feet and pedorthist referrals lifting diabetic footwear demand?

Four forces add 4.6% a year to diabetic footwear pair volume through 2035: diabetes prevalence supplies 1.49 points, foot-risk screening and referral 1.27, online direct-to-consumer selling 1.08 and Asia Pacific clinic build-out 0.76. Prevalence is the steadiest leg and the only one fixed by epidemiology.

Prevalence first. The International Diabetes Federation (IDF) Diabetes Atlas, 11th edition counts 589 million adults aged 20 to 79 with diabetes and projects 853 million by 2050; that path compounds at 1.49% a year, and Douglas Insights credits exactly 1.49 points of diabetic footwear volume growth to it. In the United States alone, Centers for Disease Control and Prevention (CDC) data put diabetes at 40.1 million people in 2023, or 12.0% of the population. The pool of feet that will someday need a depth pair is large and still growing.

Screening and referral second, worth 1.27 points. Coverage criteria reward documentation: a prior ulcer, a prior amputation, or neuropathy with callus, deformity or poor circulation qualifies a patient for diabetic footwear each calendar year. As more primary-care visits record a monofilament test, more patients cross that line, and each qualifying patient is a recurring buyer of one shoe pair and up to three insert pairs. Undiagnosed diabetes still runs at about 252 million adults worldwide, so every gain in diagnosis widens the funnel.

Online selling third, at 1.08 points. Orthofeet opened its direct-to-consumer website in 2015, and brand sites now list diabetic footwear with free shipping, 30-day or 60-day wear tests and health savings account (HSA) or flexible spending account (FSA) eligibility. Ownership change sharpens the push: Enovis completed the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners on 8 October 2025 for up to USD 60 million, USD 45 million of it upfront, and a stand-alone owner has every reason to grow retail pairs.

Asia Pacific clinic capacity fourth, worth 0.76 points. Three in four adults with diabetes live in low- and middle-income countries, where podiatry and pedorthic clinics are still thin. Each new foot clinic in India, China or Southeast Asia adds a dispensing point. Douglas Insights expects that build-out to lift Asia Pacific pair growth to 8.45% a year in value terms, against 4.95% in North America. A single trained pedorthist fitting 6 patients a day across 240 working days dispenses about 5,760 diabetic footwear pairs a year once insert refills are counted, so staffing, not demand, sets the pace.

Which A5500 claim denials and offloading devices restrain diabetic footwear volumes?

Documentation denials remove 0.42 points a year from diabetic footwear volume growth, and offloading devices that replace shoes during ulcer healing remove a further 0.21 points. Without both restraints, pair growth would run near 5.23% rather than 4.6%. A fee-schedule ceiling also trims 0.35 points from the price leg.

Paperwork is the largest drag. A Medicare contractor review of A5500, A5512 and A5513 claims from 1 July to 30 September 2024 found an average error rate of 33.45% across supplier-specific probes, as CGS Medicare reported. The OIG audit announced on 29 May 2026 cites high improper payment rates for diabetic footwear in both 2024 and 2025, mostly for insufficient documentation. Suppliers facing a one-in-three denial rate turn away marginal patients, which is where the 0.42 points go.

Clinical guidance takes the second slice. The 2023 offloading guideline of the International Working Group on the Diabetic Foot (IWGDF) tells clinicians not to use conventional or standard therapeutic footwear to heal a plantar forefoot or midfoot ulcer, favouring knee-high offloading devices that lowered plantar pressure by 239 kPa against therapeutic footwear. An estimated 20 million people a year live with a diabetes-related foot ulcer, and during healing they wear a walker, not a diabetic shoe; the substitution removes 0.21 points.

How much does a Medicare depth-inlay pair cost against a retail diabetic shoe?

A depth-inlay diabetic shoe pair is worth USD 177.70 at the 2025 Medicare-method fee, a custom-molded pair USD 532.94, and retail diabetic footwear lists between about USD 60 and USD 180 a pair. The blended manufacturer price is USD 72.86, pulled down by low-priced insert pairs.

The Montana Medicaid podiatry fee schedule, set by the Medicare method and effective 1 January 2025, pays USD 88.85 per depth-inlay shoe under A5500 and USD 266.47 per custom-molded shoe under A5501. A direct-formed multi-density insert (A5512) earns USD 36.24, so a pair is USD 72.48, while custom-molded or computer-aided manufacturing (CAM) carved inserts (A5513 and A5514) earn USD 54.08 each. Shoe modifications such as a rocker bottom or metatarsal bar pay USD 45.26.

Retail bands are close to the payer bands. Dr. Comfort listed diabetic styles from USD 69.99 to USD 159.99 on its own site, Drew Shoe showed new styles at USD 150.00 to USD 180.00, and Aetrex ranged from USD 59.95 to USD 164.95. Douglas Insights puts the manufacturer share of those prices near half, which is why the blended diabetic footwear price sits at USD 72.86 and climbs only 1.4% a year to USD 83.73 by 2035.

Which companies supply diabetic footwear after the Dr. Comfort sale?

With a 9.8% share of 2025 revenue, Dr. Comfort leads diabetic footwear, and the top three suppliers hold 23.3%, by Douglas Insights estimates. None of the six named companies discloses footwear revenue, so shares rest on catalogue depth, payer-code coverage and channel reach.

Dr. Comfort, now owned by Promus Equity Partners after the 8 October 2025 closing, sells extra-depth diabetic shoes, prescription and non-prescription inserts and custom solutions from an in-house lab, which keeps it the default supplier for many durable medical equipment suppliers. Orthofeet holds an estimated 7.4%: founded in 1984 by Ron and Michael Bar, it spent 16 years on podiatry orthotics before launching footwear in 2000. Drew Shoe, trading since 1875, calls itself the number one provider of orthopedic and diabetic shoes and sells added-depth and double-depth fits.

Aetrex builds its footwear from more than 50 million foot scans taken on its Albert scanners, which places the brand inside pedorthic stores. Apex, based in Mesa, Arizona, sells diabetic shoes, inserts and socks to people with neuropathy. DARCO International, founded by podiatrist H. Darrel Darby, supplies GentleStep extra-depth shoes and wound care shoe systems, anchoring the healing segment at an estimated 3.2% share.

Where is diabetic footwear growing fastest, from Medicare suppliers to Asia Pacific clinics?

North America leads diabetic footwear with USD 1.22 billion in 2025, or 40.7% of revenue, while Asia Pacific grows fastest at 8.45% a year to USD 1.46 billion by 2035. Payer-funded depth pairs anchor the leader; untreated neuropathy volume drives the challenger.

North America earns USD 1.22 billion today and grows 4.95% a year to USD 1.98 billion, held back by audit pressure on claims. Europe follows with USD 808.9 million, or 26.9%, and reaches USD 1.32 billion at 5.05%, with national health systems paying for custom-molded diabetic shoes after ulcers. Asia Pacific’s USD 649.5 million in 2025 more than doubles to USD 1.46 billion because the region holds most of the world’s adults with diabetes and the fewest foot clinics per patient.

Latin America adds USD 189.4 million in 2025 and grows 6.85% to USD 367.4 million. The wildcard is the Middle East and Africa at USD 135.3 million: Gulf states carry some of the highest diabetes rates anywhere, and if their insurers fund depth pairs the region’s 7.57% growth to USD 280.6 million is a floor rather than a ceiling.

Which dispensing channel sells more diabetic shoes, the pedorthist or the website?

Podiatry and pedorthic clinics still sell most diabetic footwear pairs, an estimated 46.2% of 2025 units, because a payer-funded pair needs a prescribing physician and a qualified fitter. Durable medical equipment suppliers take 24.5%, online direct-to-consumer 18.4% and retail pharmacies 10.9%.

Online direct-to-consumer is the channel to watch. Douglas Insights models it growing near 9% a year in pairs, against about 3% for clinic dispensing, because cash buyers skip the certification step and buy on wear-test terms. Retail pharmacies keep a steady 10.9% through diabetic socks, slippers and over-the-counter inserts.

Why does a healed foot ulcer turn a patient into a lifelong diabetic footwear buyer?

About 20 million people a year live with a diabetes-related foot ulcer, according to the IWGDF, and each healed ulcer qualifies that patient for funded diabetic footwear every year that follows. The prior-ulcer criterion is the single most common route into the depth-shoe benefit.

Medicare coverage pays for one extra-depth pair plus three insert pairs, or one custom-molded pair plus two extra insert pairs, per calendar year once diabetes-related foot disease is certified. A patient who heals at 60 can claim the allowance for decades. Douglas Insights counts each certified patient as about 4 diabetic footwear pairs a year, which is why insert revenue grows faster than shoe revenue.

What does the 2035 diabetic footwear forecast look like if insert refills slow or Asia scales faster?

The base case reaches USD 5.42 billion in 2035. A slower case at 3.3% pair growth and 1.0% price growth ends at USD 4.60 billion, and a faster case at 5.9% and 1.8% ends at USD 6.38 billion. Pair growth decides most of the gap.

One extra point of annual pair growth adds about USD 541 million to the 2035 diabetic footwear value; one point less removes about USD 496 million. The slower path assumes the OIG audit of 29 May 2026 tightens supplier documentation nationwide and pushes denial rates up. The faster path assumes Promus uses its 8 October 2025 purchase of Dr. Comfort to scale online selling and that Asia Pacific clinics multiply.

Published forecasts for the category run between 6.01% and 9.8% a year. Our 6.06% sits at the bottom of that band because we price pairs at manufacturer level and keep insert refills inside the 4.6% volume leg rather than counting them twice.

Which Medicare, TRICARE and Medicaid rules decide a diabetic footwear claim?

Each of 3 United States payer rulebooks funds 1 diabetic footwear shoe pair a year with inserts: Medicare Part B, TRICARE and state Medicaid. Medicare patients pay 20% coinsurance after the Part B deductible when the supplier accepts assignment and the prescribing paperwork is complete.

Medicare requires a diabetes doctor to certify the need and a podiatrist or other qualified doctor to order the shoes, and it pays only enrolled suppliers. The TRICARE policy manual mirrors the allowance: one custom-molded pair with two insert pairs, or one extra-depth pair with three insert pairs, with a rocker bottom or metatarsal bar allowed in place of one insert pair. New York Medicaid aligned its limits at one shoe pair and two insert pairs a year, effective 1 April 2025, as its eMedNY provider update states.

Outside the United States, diabetic footwear follows clinical guidelines more than coverage codes. The IWGDF guideline steers ulcer healing toward offloading devices, which shapes demand for wound care and healing shoes in Europe and Asia Pacific.

Douglas Exclusive: the Diabetic Footwear Pair-Year Reimbursement Register

The Pair-Year Reimbursement Register is a Douglas Insights model built from 13 sourced inputs: 10 Medicare-method fee lines effective 1 January 2025 and 3 coverage rulebooks. It prices what one fully used diabetic footwear allowance is worth to a supplier in a calendar year, by option.

The register’s first finding: inserts carry 55.0% of the value of the most common diabetic footwear allowance, USD 217.44 of USD 395.14. The second: Medicare’s USD 143 million over 2024 and 2025 is about USD 71.5 million a year, enough for roughly 181,000 fully used depth-shoe allowances by our arithmetic. Against 40.1 million Americans with diabetes, funded diabetic footwear reaches a thin slice, so most pairs are paid in cash.

How we count diabetic footwear pairs: which receipts add up to USD 3.01 billion?

Our model counts 41.27 million diabetic footwear pairs in 2025 at USD 72.86 each, which gives USD 3.01 billion; pairs compound at 4.6% and price at 1.4% to USD 5.42 billion in 2035. Five regions and five product segments each reconcile to that total.

Inputs: 2 prevalence series (IDF and CDC), 10 fee lines, 3 coverage rulebooks, 1 contractor error rate, 1 OIG payment total and 3 brand price lists, 20 data points in all, modelled across five regions. Pairs reach 43.17 million in 2026 and 64.71 million in 2035. Cross-check one: the 1.49% prevalence leg matches the IDF path from 589 million to 853 million adults. Cross-check two: the blended USD 72.86 sits 59% below the USD 177.70 depth-pair fee, consistent with insert pairs making up most units. Segment values for 2035 sum to within 0.31% of the global figure.

Related studies include the Medical Grade Footwear Market, which adds non-diabetic orthopaedic shoes, the Wound Care Market for ulcer dressings, and the Footwear Market for the consumer shoe trade that diabetic footwear sits beside.

Sources

1. International Diabetes Federation IDF Diabetes Atlas 11th edition release (2025)
2. Enovis Enovis completes sale of Dr. Comfort (2025)
3. HHS Office of Inspector General Medicare payments to suppliers for therapeutic shoes (OAS-26-09-070) (2026)
4. Medicare.gov Therapeutic shoes and inserts coverage (2026)
5. Montana Medicaid Podiatry services fee schedule, January 2025 (2025)
6. New York State Medicaid (eMedNY) Diabetic footwear update (2025)
7. CGS Medicare Therapeutic shoes and inserts TPE status report (2024)
8. CDC National diabetes statistics (2025)
9. International Working Group on the Diabetic Foot IWGDF offloading guideline 2023 (2023)
10. Defense Health Agency TRICARE Policy Manual Ch. 8 Sec. 8.2 (2025)